Diagnostic work-up of bone metastases of genitourinary tumors and their treatment with bisphosphonates. Interdisciplinary consensus conference, Frankfurt, 2006;Diagnostik von knochenmetastasen urologischer tumoren und deren behandlung mit bisphosphonaten. Interdisziplinäre konsensuskonferenz Frankfurt 2006

Urologe - Ausgabe A

Volumn 45, Issue 12, 2006, Pages 1527-1531

  Weissbach L ^a  

^a EuromedClinic   (Germany)

Author keywords

Bisphosphonate therapy; Bone metastases; Combination therapy; Genitourinary tumors; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADD ON THERAPY; BONE METASTASIS; BONE NECROSIS; BONE SCINTISCANNING; CONFERENCE PAPER; GERMANY; HORMONE SENSITIVITY; HUMAN; INTERDISCIPLINARY COMMUNICATION; KIDNEY CARCINOMA; MOUTH HYGIENE; NEPHROTOXICITY; PROSTATE CANCER; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; GERMANY; HUMANS; PATIENT CARE TEAM; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; UROGENITAL NEOPLASMS;

EID: 33845672686     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1229-x     Document Type: Conference Paper

References (18)

1. Abu-Id MH, Acil Y, Gottschalk J, Kreusch T (2006) Bisphosphonatassoziierte Osteonekrose des Kiefers. MundKieferGesichtsChir 10: 73-81
2. Adamietz IA (2005) Palliative Radiotherapie. In: Bamberg M, Molls M, Sack H (Hrsg) Radioonkologie. Zuckerschwerdt, München Wien New York, S 1117-1156
3. Bamias A, Kastritis E, Bamia C et al. (2005) Osteonecrosis of the jaw in cancer after treatment with Bisphosphonates: Incidence and risk factors. J Clin Oncol 23: 8580-8587
4. Feil G, Feyerabend S, Anastasiadis AG et al. (2006) Bone turnover parameters ICTP and PINP are promising serum markers for diagnosis and therapy monitoring of bone metastasis in prostate cancer patients. Europ Urol 5 [Suppl 2]: 57
5. Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma. Clin Orthop Relat Res 431: 187-192
6. Greenberg MS (2004) Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Pathol Oral Radiol Endod 98: 259-260
7. Grötz KA, Al-Nawas B, Kutzner J et al. (2001) Ätiologie der infizierten Osteoradionekrose des Kiefer-Gesichts-Bereiches: Einfluss der periradiotherapeutischen Betreuung. Dtsch Zahnärztl Z 56: 43-46
8. Grötz KA, Diel IJ (2005) Osteonekrose des Kiefers unter Bisphosphonat-Langzeittherapie. Onkologie 8: 52-55
9. Heine K, Wolff JM (2005) Das Nachsorgeprinzip beim metastasierten Prostatakarzinom. Urologe 44: 1009-1017
10. Höffken H (2004) Nuklearmedizinische Therapieoptionen in der Palliativtherapie des Prostatakarzinoms. In: Heidenreich A (Hrsg) Palliative Therapiestrategien beim Prostatakarzinom. Uni-Med-Verlag, Bremen, S 74-95
11. Jung ST, Ghert MA, Harrelson JM, Scully SP (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409: 223-231
12. Koswig S, Budach V (1999) Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10-mal 3 Gy vs. 1-mal 8 Gy). Strahlenther Onkol 175: 500-508
13. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98: 962-969
14. Lipton A, Colombo-Berra A, Bukowski RM et al. (2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10 [Suppl]: 6397-6403
15. Ruggiero S, Gralow J, Marx RE et al. (2006) Practical Guidelines fort he prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Practice 2: 7-14
16. Saad F (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882
17. Saad F, Small EJ, Smith MR (2006) Zoldedronic acid compared with Pamidronate in patients with prostate cancer and bone metastases: effects on skeletal complications and bone markers. Europ Urol 5 [Suppl 2]: 57
18. Small EJ, Smith MR, Seaman JJ et al. (2003) Combined Analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21(23): 4277-4284